Blood and Marrow Transplantation:

Abdelghani Tbakhi, MD, FCAP


Chairman, Department of Cell Therapy & Applied Genomics Institution Principal Investigator- EBMT

Mahmoud Sarhan, MD

BMT Program Director



KING HUSSEIN CANCER FOUNDATION KING HUSSEIN CANCER CENTER




The 4th WBMT Congress and Workshop – Riyadh, KSA - January 15-17, 2017
























Jordan Population

- Central Region:
 - Amman
 - Az Zarqa
 - Al Balqa
 - Madaba



Jordan Population

- Central Region:
 - Amman
 - Az Zarqa
 - Al Balqa
 - Madaba










GDP (current US\$)

World Bank national accounts data, and OECD National Accounts data files.

License: Open







GINI index - Jordan


GINI index in Jordan was last measured at **35.43** in 2010, according to the World Bank




Note: a Gini index of 0 represents perfect equality, while an index of 100 implies perfect inequality.

http://www.tradingeconomics.com/jordan/gini-index-wb-data.html, last visited January 11, 2017


Population Pyramid of Jordan






Population Pyramid, Jordan 2014

Population Pyramid of Jordan




Population Pyramid, Jordan 2014










Jordanian Department of Statistics, Jan 2016


Annual BMT Numbers









KHCC / BMT per year







794 (59.4%)

Autologous 543 (40.6%)







Allogeneic BMT



Donor Source	Total	Adults	Pediatrics
Matched Sibling	638 (80.4%)	291	347
Matched Other Relative	66 (8.3%)	10	56
Mismatched Relative (one antigen mismatch)	19 (2.4%)	2	17
Haploidentical	37 (4.7%)	5	32
UCBU	31 (3.9%)	3	28
MUD	3 (0.33%)	2	1
TOTAL	794	<mark>313 (</mark> 39%)	<mark>481 (61%)</mark>



Biol Blood Marrow Transplant. 2013 Feb;19(2):221-6. doi: 10.1016/j.bbmt.2012.09.009. Epub 2012 Sep 28.

Probability of finding an HLA-matched donor in immediate and extended families: the Jordanian experience.

Elbjeirami WM¹, Abdel-Rahman F, Hussein AA.

Author information

Abstract

Information regarding the probability of finding HLA-matched related donor for a patient awaiting hematopoietic stem cell transplantation (HSCT) in developing countries is scanty. We performed a retrospective review of HLA genotypes and related data for 1254 consecutive patients and their families at King Hussein Cancer Center in Amman, Jordan, between 2003 and 2011 to evaluate the chance of finding HLA-matched donor. The median family size was 5 for all patients in the study (range, 1-14), and the average number of donors was 1.4 ± 0.9 for pediatric patients and 1.6 ± 0.9 for adults. Overall, the probability of finding an HLA-matched related donor at our center was 65.5% (60.6% in pediatric patients and 74% in adults). Of the total identified donors, 18% were nonsibling donors after an immediate and/or extended family search in the pediatric group, and 6% were nonsibling donors in the adult group. Overall, 13% of donors were nonsibling donors. We conclude that the probability of finding a matched related donor for HSCT in Jordan is much higher than that reported in Western countries and Asia (65% versus 25%). We expect a similar trend in other developing and Arab countries. We recommend integrating an extended family search

٠ Save items ☆ Add to Favorites -Similar articles Contribution of HLA-Biol Blood Marrow Transplant. ...] Successful transplantation of HLA-matched and [Blood. 1996] Unrelated stem cell transplant [Haematologica. 2007] Review HLA and bone marrow [J Assoc Physicians India. 2002] Review Selection of unrelated bone m: [Transpl Immunol. 2002] See reviews... See all...

ELSEVIER

Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All





Total BMT (2003-2016) 1337 Malignant **Non-Malignant** 324 (24.2%) 1013 (75.8%)

BMT Indications - KHCC




Disease	Number	Percentage
Leukemia	377	(28.2%)
Lymphoma	314	(23.3%) -63.5%
Plasma cell Disorders	160	(12%)
Solid tumors	118	(9%)
MDS/MPN	44	(3%)
Hemoglobinopathies	148	(11.1%)
Bone Marrow Failure	118	(9%)
Immunodeficiency Disorders	46	(3%)
Inherited Disorders	12	(1.4%)
TOTAL	1337	



BMT Indications - RMS

Immunodeficiency cases (87)



■ LAD ■ HIgM ■ CID ■ SCID ■ CGD ■ Griscelli ■ FHLH ■ CHS ■ Kostmann's ■ SCN

Courtesy of DR. Adel Al-Wahadneh, RMS





Total BMT (Jan 2013- Dec 2016) = 53


Allogeneic (37, 70%)	Autologous (16, <mark>30%</mark>)			
Adults (14, 26%)	Pediatrics (39, 74%)			
Malignant (31, 58%)	Non Malignant (22, 42%)			
Disease Category				
Leukemias	13 (<mark>24.5</mark> %)			
Lymphomas	8 (15.1%)			
Solid Tx	8 (15.1%)			
MDS	2 (<mark>3.8%</mark>)			
Hemoglobinopathy	8 (15.1%)			
B.M.F	8 (15.1%)			
Inherited /Autoimmun Disorders	6 (11.3%)			

Average Cost for BMT (US \$)

Type of Transplant	Auto	Allo
Evaluation pre Admission	15637.13	19546.41
Transplant Admission	36734.43	45918.04
Post BMT Discharge – Day 100	19811.83	22783.61
Donor workup		4758.64
Total Average Cost	72183.39	93006.70


CAUTI Rates











BMT in Jordan - Challenges



- Financial issues
 - Jordanians
 - -Non-Jordanians



- -Medication prices (e.g., BEAM)
- Space and bed availability
- Accommodations (patients and families)

KHCC: Future Plans





182 Single beds (+ 172 existing => 350)(including AICU, PICU)
6 Operating Rooms
1 Emergency Room (19 beds)
1 Outpatient Building

Research Interests



- Surgical complications of BMT
- BMT of Myeloma and lymphomas
- BMT of Thalassemia
- CMV reactivation in Auto BMT
- Bacterial infections
- BMT Conditioning and Mobilization
- Histocompatibility & Immunogenetics
- Cord Blood banking
- Stem cell processing

Acknowledgments



KHCC

Mahmoud Sarhan, **MD**, BMT Program Director/

BMT Consultant/ Pediatrics

Rawad Rihani, MD Eman Khattab, MD Mayada Abu Shanap, MD Ayad Hussein, MD Abdul Hadi Al Zaben, MD

BMT Consultant/ Adults

Fawzi Abdel Rahman, Prev. BMT Program Director Husam Abu Jazar, MD Khaled Halahleh, MD Mohammed Ma'koseh, MD Omar Al Rawi, MD

Nursing Department Haitham Abu Haq, BMT Unit Head Nurse Maha Yousef, BMT Program Coordinator/ Adults Fadia Al Sheab, BMT program Coordinator/ Pediatric

Department of Cell Therapy & Applied Genomics

Abdelghani Tbakhi, MD, FCAP, Chairman, Shanta Sharma, PH.D., Amal Afifi, Ph.D, Wafa Elbjeirami, Ph.D Salah Albohisi, Lab Manager

OSAR Nilly Hussein, BMT Program Data Manager

Pharmacy Rula Najjar, BMT Pharm. D

Royal Medical Services Adel Wahadneh, MD Nazmi Kamal, MD

University of Jordan Abdulla Al-Abbadi

Private Sector Mohammad Salameh Maisara Alqam





